Hyperphosphatemia

6
Pipeline Programs
5
Companies
18
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Akebia Therapeutics
Akebia TherapeuticsCAMBRIDGE, MA
1 program
1
Ferric Citrate 1 gram Oral TabletPhase 41 trial
Active Trials
NCT04922645CompletedEst. Sep 2022
Bayer
BayerLEVERKUSEN, Germany
4 programs
1
1
FosrenolPhase 31 trial
BAY 77-1931Phase 21 trial
Lanthanum CarbonateN/A5 trials
Lanthanum CarbonateN/A1 trial
Active Trials
NCT02237534Unknown60Est. Sep 2023
NCT01110629Completed143Est. Nov 2011
NCT01053676Completed59Est. Apr 2010
+5 more trials
Astellas
AstellasChina - Shenyang
1 program
1
ASP1585Phase 24 trials
Active Trials
NCT02531204Completed60Est. Feb 2015
NCT01742611Completed105Est. Apr 2015
NCT00892749Completed248Est. Sep 2010
+1 more trials
DS
Daiichi SankyoChina - Shanghai
1 program
1
DS-2330b PIBPhase 11 trial
Active Trials
NCT03305471Completed40Est. Jan 2019
CP
Chugai PharmaJapan - Tokyo
1 program
1
EOS789Phase 11 trial
Active Trials
NCT02965053Completed26Est. Aug 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Akebia TherapeuticsFerric Citrate 1 gram Oral Tablet
BayerLanthanum Carbonate
AstellasASP1585
BayerFosrenol
BayerLanthanum Carbonate
AstellasASP1585
BayerLanthanum Carbonate
BayerLanthanum Carbonate
AstellasASP1585
BayerLanthanum Carbonate
BayerBAY 77-1931
Daiichi SankyoDS-2330b PIB
Chugai PharmaEOS789
AstellasASP1585
BayerLanthanum Carbonate

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 5,537 patients across 18 trials

NCT04922645Akebia TherapeuticsFerric Citrate 1 gram Oral Tablet

Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants

Start: Jun 2021Est. completion: Sep 2022
Phase 4Completed
NCT02237534BayerLanthanum Carbonate

Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia

Start: Sep 2014Est. completion: Sep 202360 patients
Phase 4Unknown
NCT01742611AstellasASP1585

Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Start: Mar 2013Est. completion: Apr 2015105 patients
Phase 3Completed
NCT01187628BayerFosrenol

Long-term Study in Chronic Kidney Disease (Extension From Study 14817)

Start: Sep 2010Est. completion: Apr 2013123 patients
Phase 3Completed
NCT01110629BayerLanthanum Carbonate

Study in Chronic Kidney Disease (CKD) Not on Dialysis

Start: Jun 2010Est. completion: Nov 2011143 patients
Phase 3Completed
NCT00892749AstellasASP1585

Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

Start: May 2009Est. completion: Sep 2010248 patients
Phase 3Completed
NCT01514851BayerLanthanum Carbonate

Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate

Start: Jan 2006Est. completion: May 2006259 patients
Phase 3Completed
NCT01518387BayerLanthanum Carbonate

Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients

Start: Jan 2006Est. completion: Jul 200643 patients
Phase 3Completed
NCT00505037AstellasASP1585

A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Start: Oct 2007Est. completion: Sep 2008156 patients
Phase 2Completed
NCT00767637BayerLanthanum Carbonate

Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone

Start: Jun 2005Est. completion: Oct 200814 patients
Phase 2Completed
NCT00769496BayerBAY 77-1931

BAY 77-1931 Long-term Extension From Phase II Study

Start: Jan 2005Est. completion: May 2008145 patients
Phase 2Completed
NCT03305471Daiichi SankyoDS-2330b PIB

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

Start: Aug 2017Est. completion: Jan 201940 patients
Phase 1Completed
NCT02965053Chugai PharmaEOS789

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

Start: Dec 2016Est. completion: Aug 201826 patients
Phase 1Completed
NCT02531204AstellasASP1585

A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules

Start: Aug 2014Est. completion: Feb 201560 patients
Phase 1Completed
NCT01053676BayerLanthanum Carbonate

Bioequivalence Study of BAY77-1931 Granule

Start: Jan 2010Est. completion: Apr 201059 patients
Phase 1Completed
NCT01955876BayerLanthanum Carbonate

Fosrenol Post-marketing Surveillance in Japan

Start: Oct 2013Est. completion: Aug 2016343 patients
N/ACompleted
NCT01412398BayerLanthanum Carbonate

Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan

Start: Apr 2009Est. completion: Sep 2016446 patients
N/ACompleted
NCT01419327BayerLanthanum Carbonate

Fosrenol Post-marketing Surveillance for Hemodialysis in Japan

Start: Mar 2009Est. completion: May 20193,267 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space